These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 38409243)
1. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma. Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243 [TBL] [Abstract][Full Text] [Related]
2. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma. Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217 [TBL] [Abstract][Full Text] [Related]
3. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma. Zhang HB; Pan JY; Zhu T Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882 [No Abstract] [Full Text] [Related]
4. Unlocking the Potential of Disulfidptosis-Related LncRNAs in Lung Adenocarcinoma: A Promising Prognostic LncRNA Model for Survival and Immunotherapy Prediction. Nie X; Ge H; Wu K; Liu R; He C Cancer Med; 2024 Oct; 13(20):e70337. PubMed ID: 39431755 [TBL] [Abstract][Full Text] [Related]
5. Construction of lncRNA prognostic model related to disulfidptosis in lung adenocarcinoma. Zhang L; Wang S; Wang L Heliyon; 2024 Aug; 10(15):e35657. PubMed ID: 39170273 [TBL] [Abstract][Full Text] [Related]
6. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer. Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096 [TBL] [Abstract][Full Text] [Related]
7. Disulfidptosis‑related lncRNA prognosis model to predict survival therapeutic response prediction in lung adenocarcinoma. Sun X; Li J; Gao X; Huang Y; Pang Z; Lv L; Li H; Liu H; Zhu L Oncol Lett; 2024 Aug; 28(2):342. PubMed ID: 38855504 [TBL] [Abstract][Full Text] [Related]
8. Disulfidptosis-associated LncRNA signature predicts prognosis and immune response in kidney renal clear cell carcinoma. Xu K; Li D; Ji K; Zhang Y; Zhang M; Zhou H; Hou X; Jiang J; Zhang Z; Dai H; Sun H Biol Direct; 2024 Aug; 19(1):71. PubMed ID: 39175011 [TBL] [Abstract][Full Text] [Related]
9. A methylation-related lncRNA-based prediction model in lung adenocarcinomas. Yang K; Liu H; Li JH Clin Respir J; 2024 Aug; 18(8):e13753. PubMed ID: 39187946 [TBL] [Abstract][Full Text] [Related]
10. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response. Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328 [TBL] [Abstract][Full Text] [Related]
11. Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma. Liu J; Li H; Zhang N; Dong Q; Liang Z Curr Med Chem; 2024; 31(25):4034-4055. PubMed ID: 38685772 [TBL] [Abstract][Full Text] [Related]
12. Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma. Pan Y; Jin X; Xu H; Hong J; Li F; Luo T; Zeng J Sci Rep; 2024 Jun; 14(1):13113. PubMed ID: 38849442 [TBL] [Abstract][Full Text] [Related]
13. Deciphering disulfidptosis: Uncovering a lncRNA-based signature for prognostic assessment, personalized immunotherapy, and therapeutic agent selection in lung adenocarcinoma patients. Ma C; Zhao H; Sun Y; Ding W; Wang H; Li Y; Gu Z Cell Signal; 2024 May; 117():111105. PubMed ID: 38369264 [TBL] [Abstract][Full Text] [Related]
14. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma. Sun D; Zhang C Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766 [TBL] [Abstract][Full Text] [Related]
15. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation. Wang Y; Xu Y; Liu C; Yuan C; Zhang Y Front Immunol; 2023; 14():1233260. PubMed ID: 37799714 [TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma. Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of disulfidptosis-related lncRNAs for predicting prognosis and response of immunotherapy in pancreatic adenocarcinoma. Guo J; Wang Y; Hou J; Zhao T; Wei Z Transl Cancer Res; 2024 Mar; 13(3):1336-1350. PubMed ID: 38617527 [TBL] [Abstract][Full Text] [Related]
18. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma. Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642 [TBL] [Abstract][Full Text] [Related]
19. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma. Ren J; Wang A; Liu J; Yuan Q Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158 [TBL] [Abstract][Full Text] [Related]
20. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma. Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]